相似文献
1
Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.
Oncologist. 2013;18(1):e3-5. doi: 10.1634/theoncologist.2012-0219.
2
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
3
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Target Oncol. 2009 Jan;4(1):37-44. doi: 10.1007/s11523-009-0104-2. Epub 2009 Jan 20.
4
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Keio J Med. 2012;61(4):120-7. doi: 10.2302/kjm.2011-0009-oa.
5
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Invest New Drugs. 2010 Aug;28(4):433-44. doi: 10.1007/s10637-009-9266-0. Epub 2009 Jun 5.
6
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005.
7
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
J Clin Oncol. 2010 Jan 10;28(2):357-60. doi: 10.1200/JCO.2009.24.7049. Epub 2009 Nov 30.
8
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.
9
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
10
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.
引用本文的文献
1
Construction and validation of a diagnostic model for rheumatoid arthritis based on mitochondrial autophagy-related genes.
Heliyon. 2024 Jan 18;10(3):e24818. doi: 10.1016/j.heliyon.2024.e24818. eCollection 2024 Feb 15.
2
Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes.
Saudi J Med Med Sci. 2022 Sep-Dec;10(3):183-191. doi: 10.4103/sjmms.sjmms_492_21. Epub 2022 Sep 7.
3
Apoptosis in Type 2 Diabetes: Can It Be Prevented? Hippo Pathway Prospects.
Int J Mol Sci. 2022 Jan 7;23(2):636. doi: 10.3390/ijms23020636.
4
Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies.
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):34-45. doi: 10.1007/s13193-019-00972-z. Epub 2019 Aug 19.
5
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.
J Immunother Cancer. 2019 Jul 10;7(1):172. doi: 10.1186/s40425-019-0643-8.
6
Viral Induced Oxidative and Inflammatory Response in Alzheimer's Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach.
Curr Neuropharmacol. 2019;17(4):352-365. doi: 10.2174/1570159X16666180419124508.
7
Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer.
Onco Targets Ther. 2017 Feb 21;10:1101-1110. doi: 10.2147/OTT.S112158. eCollection 2017.
8
Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib.
Korean J Intern Med. 2018 Jan;33(1):211-213. doi: 10.3904/kjim.2015.276. Epub 2016 Nov 25.
本文引用的文献
1
Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review.
Drugs Aging. 2012 May 1;29(5):343-58. doi: 10.2165/11599350-000000000-00000.
2
Kinase inhibitors in the treatment of immune-mediated disease.
F1000 Med Rep. 2012;4:5. doi: 10.3410/M4-5. Epub 2012 Mar 1.
3
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model.
World J Gastroenterol. 2011 Nov 28;17(44):4858-66. doi: 10.3748/wjg.v17.i44.4858.
4
Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification.
Ann Rheum Dis. 2012 Jun;71(6):891-8. doi: 10.1136/ard.2011.149849. Epub 2011 Nov 29.
5
Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.
Clin Ther. 2011 Jun;33(6):679-707. doi: 10.1016/j.clinthera.2011.05.044.
6
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway.
Toxicol Appl Pharmacol. 2011 Mar 1;251(2):130-6. doi: 10.1016/j.taap.2010.12.011. Epub 2010 Dec 31.
7
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.
Genes Dev. 2010 Dec 1;24(23):2666-77. doi: 10.1101/gad.1964410.
8
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis.
Nat Rev Rheumatol. 2011 Jan;7(1):33-42. doi: 10.1038/nrrheum.2010.196. Epub 2010 Nov 30.
9
Improvement of psoriasis in a lung cancer patient treated with erlotinib.
Eur J Dermatol. 2010 Mar-Apr;20(2):243-4. doi: 10.1684/ejd.2010.0882. Epub 2010 Feb 2.
10
Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data.
PLoS Comput Biol. 2009 Dec;5(12):e1000591. doi: 10.1371/journal.pcbi.1000591. Epub 2009 Dec 4.
Zotero 插件